Heterogeneous cell-cycle behavior in response to UVB irradiation by a population of single cancer cells visualized by time-lapse FUCCI imaging

Cell Cycle

Volumn 14, Issue 12, 2015, Pages 1932-1937

  Miwa, Shinji ^a,b,c   Yano, Shuya ^a,b,d   Kimura, Hiroaki ^c   Yamamoto, Mako ^a,b   Toneri, Makoto ^a,b   Murakami, Takashi ^a,b   Hayashi, Katsuhiro ^c   Yamamoto, Norio ^c   Fujiwara, Toshiyoshi ^d   Tsuchiya, Hiroyuki ^c   Hoffman, Robert M ^a,b  

^a ANTICANCER INC   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell cycle; FUCCI; HeLa; Heterogeneity; Mitosis; Survival analysis; Time lapse imaging; UVB

Indexed keywords

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL POPULATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; HELA CELL LINE; MITOSIS; RADIATION DOSE; TIME LAPSE FLUORESCENCE UBIQUITINATION BASED CELL CYCLE IMAGING; TIME LAPSE IMAGING; ULTRAVIOLET B RADIATION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CHEMISTRY; DRUG EFFECTS; HUMAN; KAPLAN MEIER METHOD; RADIATION RESPONSE; UBIQUITINATION; ULTRAVIOLET RADIATION;

CISPLATIN; DOXORUBICIN; FLUORESCENT DYE;

APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CISPLATIN; DOXORUBICIN; FLUORESCENT DYES; G1 PHASE; G2 PHASE; HELA CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MICROSCOPY, CONFOCAL; MITOSIS; S PHASE; UBIQUITINATION; ULTRAVIOLET RAYS;

EID: 84943745164     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1033598     Document Type: Article

References (22)

1. Heppner GH, Miller BE. Therapeutic implications of tumor heterogeneity. Semin Oncol 1989; 16: 91-105.
2. Schöber C, Gibbs JF, Yin MB, Slocum HK, Rustum YM. Cellular heterogeneity in DNA damage and growth inhibition induced by ICI D1694, thymidylate synthase inhibitor, using single cell assays. Biochem Pharmacol 1994; 48: 997-1002; PMID: 8093112; http://dx. doi. org/10. 1016/0006-2952(94)90370-0.
3. Slocum HK, Parsons JC, Winslow EO, Broderick L, Minderman H, Tóth K, Greco WR, Rustum YM. Time-lapse video reveals immediate heterogeneity and heritable damage among human ileocecal carcinoma HCT-8 cells treated with raltitrexed (ZD1694). Cytometry 2000; 41: 252-60; PMID: 11084610; http://dx. doi. org/10. 1002/1097-0320(20001201)41: 4%3c252:: AID-CYTO3%3e3. 0. CO; 2-X.
4. Yin MB, Voigt W, Panadero A, Vanhoefer U, Frank C, Pajovic S, Azizkhan J, Rustum YM. p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). Mol Pharmacol 1997; 51: 630-6; PMID: 9106628.
5. Matsui SI, Arredondo MA, Wrzosek C, Rustum YM. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res 1996; 56: 4715-23; PMID: 8840989.
6. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008; 132: 487-98; PMID: 18267078; http://dx. doi. org/10. 1016/j. cell. 2007. 12. 033.
7. Miwa S, Yano S, Kimura H, Yamamoto M, Toneri M, Matsumoto Y, Uehara F, Hiroshima Y, Murakami T, Hayashi K, et al. Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time FUCCI imaging. Cell-Cycle 2015; 14: 621-9; PMID: 25551170; http://dx. doi. org/10. 4161/15384101. 2014. 991604, Epub ahead of print.
8. Uehara F, Miwa S, Tome Y, Hiroshima Y, Yano S, Yamamoto M, Efimova E, Matsumoto Y, Maehara H, Bouvet M, et al. Comparison of UVB and UVC effects on the DNA damage-response protein 53BP1 in human pancreatic cancer. J Cell Biochem 2014; 115: 1724-8; PMID: 24819034; http://dx. doi. org/10. 1002/jcb. 24837.
9. Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle 2005; 4: 269-78; PMID: 15655345.
10. Blagosklonny MV. Tissue-selective therapy of cancer. Br J Cancer 2003; 89: 1147-51; PMID: 14520435; http://dx. doi. org/10. 1038/sj. bjc. 6601256.
11. Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today 2003; 8: 1104-7; PMID: 14678733; http://dx. doi. org/10. 1016/S1359-6446(03)02806-X.
12. Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle 2008; 7: 1307-12; PMID: 18487952; http://dx. doi. org/10. 4161/cc. 7. 10. 6250.
13. Blagosklonny MV. Teratogens as anti-cancer drugs. Cell Cycle 2005; 4: 1518-21; PMID: 16258270; http://dx. doi. org/10. 4161/cc. 4. 11. 2208.
14. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrugresistant cells but protects normal cells. Leukemia 2001; 15: 936-41; PMID: 11417480; http://dx. doi. org/10. 1038/sj. leu. 2402127.
15. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia 2006; 20: 385-91; PMID: 16357832; http://dx. doi. org/10. 1038/sj. leu. 2404075.
16. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 2007; 6: 1684-90; PMID: 18344680; http://dx. doi. org/10. 4161/cbt. 6. 11. 5167.
17. 1 resulting in chemoresistance demonstrated by realtime FUCCI imaging. Cell Cycle 2014; 13: 953-60; PMID: 24552821; http://dx. doi. org/10. 4161/cc. 27818.
18. Yano S, Zhang Y, Miwa S, Tome Y, Hiroshima Y, Uehara F, Yamamoto M, Suetsugu A, Kishimoto H, Tazawa H, et al. Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. Cell Cycle 2014; 13: 2110-19; PMID: 24811200; http://dx. doi. org/10. 4161/cc. 29156.
19. Yano S, Miwa S, Mii S, Hiroshima Y, Uehara F, Kishimoto H, Tazawa H, Zhao M, Bouvet M, Fujiwara T, Hoffman RM. Cancer cells mimic in vivo spatial-temporal cell-cycle phase distribution and chemosensitivity in 3-dimensional Gelfoam-histoculture but not 2-dimensional culture as visualized with real-time FUCCI imaging. Cell Cycle 2015; 14: 808-19: PMID: 25564963; http://dx. doi. org/10. 4161/15384101. 2014. 989946.
20. Yano S, Zhang Y, Zhao M, Hiroshima Y, Miwa S, Uehara F, Kishimoto H, Tazawa H, Bouvet M, Fujiwara T, et al. Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy. Cell Cycle 2014; 13: 3958-63; PMID: 25483077; http://dx. doi. org/10. 4161/15384101. 2014. 964115, in press.
21. Miwa S, Yano S, Tome Y, Sugimoto N, Hiroshima Y, Uehara F, Mii S, Kimura H, Hayashi K, Efimova EV, et al. Dynamic color-coded fluorescence imaging of the cell-cycle phase mitosis, and apoptosis demonstrates how caffeine modulates cisplatinum efficacy. J Cell Biochem 2013; 114: 2454-60; PMID: 23696238; http://dx. doi. org/10. 1002/jcb. 24593.
22. Uchugonova A, Duong J, Zhang N, König K, Hoffman RM. The bulge area is the origin of nestin-expressing pluripotent stem cells of the hair follicle. J Cell Biochem 2011; 112: 2046-50; PMID: 21465525; http://dx. doi. org/10. 1002/jcb. 23122.